NOTICE: Labnodes now supports vumc.org email addresses. If your email changed, please update your profile today.
Robert Beauchamp
Principal Investigator
Last active: 10/31/2018

  1. Frequent BRAF mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma. Idrees K, Padmanabhan C, Liu E, Guo Y, Gonzalez RS, Berlin J, Dahlman KB, Beauchamp RD, Shi C (2018) J Surg Oncol 117(2): 284-289
    › Citation · 28940307 (PubMed)
  2. APC Inhibits Ligand-Independent Wnt Signaling by the Clathrin Endocytic Pathway. Saito-Diaz K, Benchabane H, Tiwari A, Tian A, Li B, Thompson JJ, Hyde AS, Sawyer LM, Jodoin JN, Santos E, Lee LA, Coffey RJ, Beauchamp RD, Williams CS, Kenworthy AK, Robbins DJ, Ahmed Y, Lee E (2018) Dev Cell 44(5): 566-581.e8
    › Citation · 29533772 (PubMed)
  3. The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer. Ma Y, Wang L, Neitzel LR, Loganathan SN, Tang N, Qin L, Crispi EE, Guo Y, Knapp S, Beauchamp RD, Lee E, Wang J (2017) Clin Cancer Res 23(8): 2027-2037
    › Citation · 27678457 (PubMed) · PMC5368030 (PubMed Central)
  4. ML327 induces apoptosis and sensitizes Ewing sarcoma cells to TNF-related apoptosis-inducing ligand. Rellinger EJ, Padmanabhan C, Qiao J, Appert A, Waterson AG, Lindsley CW, Beauchamp RD, Chung DH (2017) Biochem Biophys Res Commun 491(2): 463-468
    › Citation · 28716733 (PubMed) · PMC5564678 (PubMed Central)
  5. Micropapillary colorectal carcinoma: clinical, pathological and molecular properties, including evidence of epithelial-mesenchymal transition. Gonzalez RS, Huh WJ, Cates JM, Washington K, Beauchamp RD, Coffey RJ, Shi C (2017) Histopathology 70(2): 223-231
    › Citation · 27560620 (PubMed)
  6. Isoxazole compound ML327 blocks MYC expression and tumor formation in neuroblastoma. Rellinger EJ, Padmanabhan C, Qiao J, Craig BT, An H, Zhu J, Correa H, Waterson AG, Lindsley CW, Beauchamp RD, Chung DH (2017) Oncotarget 8(53): 91040-91051
    › Citation · 29207623 (PubMed) · PMC5710904 (PubMed Central)
  7. cFLIP critically modulates apoptotic resistance in epithelial-to-mesenchymal transition. Padmanabhan C, Rellinger EJ, Zhu J, An H, Woodbury LG, Chung DH, Waterson AG, Lindsley CW, Means AL, Beauchamp RD (2017) Oncotarget 8(60): 101072-101086
    › Citation · 29254146 (PubMed) · PMC5731856 (PubMed Central)
  8. Evaluation of frozen tissue-derived prognostic gene expression signatures in FFPE colorectal cancer samples. Zhu J, Deane NG, Lewis KB, Padmanabhan C, Washington MK, Ciombor KK, Timmers C, Goldberg RM, Beauchamp RD, Chen X (2016) Sci Rep : 33273
    › Citation · 27623752 (PubMed) · PMC5021945 (PubMed Central)
  9. Comparison of Nanostring nCounter® Data on FFPE Colon Cancer Samples and Affymetrix Microarray Data on Matched Frozen Tissues. Chen X, Deane NG, Lewis KB, Li J, Zhu J, Washington MK, Beauchamp RD (2016) PLoS One 11(5): e0153784
    › Citation · 27176004 (PubMed) · PMC4866771 (PubMed Central)
  10. Adenoma-like adenocarcinoma: a subtype of colorectal carcinoma with good prognosis, deceptive appearance on biopsy and frequent KRAS mutation. Gonzalez RS, Cates JM, Washington MK, Beauchamp RD, Coffey RJ, Shi C (2016) Histopathology 68(2): 183-90
    › Citation · 25913616 (PubMed) · PMC4619179 (PubMed Central)